🔍

Arvee Laboratories (India) Limited (ARVEE)

₹226.20 +0.13% last close, 16 Oct

📊 NSE: ARVEE 🏢 Chemicals 📢 Latest filing: 30 Sep 2026 📝 Analysis written: 13 Dec 2025

Q2 FY27 results

📅 Next results: 03 Nov 2026 (board meeting)

Arvee Laboratories (India) Limited's board meets on 3 Nov 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Arvee Laboratories' revenue was ₹17.2 Cr (+130.3% year on year, +59.5% on the previous quarter), and net profit ₹1.7 Cr (+896.5% year on year); the operating margin was 14.5%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹17.2	+130.3%	+59.5%
Operating profit	₹2.5	+634.0%	+126.9%
Net profit	₹1.7	+896.5%	+225.8%
EPS (₹)	1.54	+926.7%	+227.7%
Operating margin	14.5%	—	—

Full quarterly financials → Results calendar →

ARVEE delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 43.82% of the ARVEE shares traded on NSE were taken to delivery, against the stock's own 20-session average of 48.42%. That is close to its usual level. Turnover was only ₹30 lakh, so a handful of trades can move this figure. Volume was 0.4 times its average, well below normal. It closed at a price band (circuit) on 3 sessions in about the last 20.

43.82%Delivery, 16 Oct

48.42%Own 20-session average

0.4×Volume vs its average

₹226.20NSE close · +0.13%

Delivery in the last 5 sessions: 53.3% · 43.2% · 57.2% · 54.1% · 43.8%

Delivery across the market →Circuit stocks →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

Arvee Laboratories AGM: All 4 Resolutions Passed With 100% Approval

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Sep 2026, 08:40 PM

Arvee Laboratories (India) Limited submitted its voting results and Scrutinizer's Report for the Annual General Meeting held on September 29, 2026. All 4 resolutions on the agenda were passed with 100% of the polled votes cast in favor. Key resolutions included the adoption of FY26 financial statements, the reappointment of retiring director Saurin Ajitbhai Gandhi, and the reappointment of Sachin Kanwarlal Kansal and Shalini Hitesh Jalan as Independent Directors. A total of 11,887,858 votes were polled across remote e-voting and poll, with zero votes cast against any resolution.

4 resolutions presented and passed with 100% votes in favor and 0 votes against
A total of 11,887,858 valid votes were polled across promoter and public categories
Reappointed Sachin Kanwarlal Kansal as Independent Director for a second 5-year term from October 1, 2026 to September 30, 2031
1,958 total shareholders were registered on the record date of September 22, 2026

💡 Track the upcoming quarterly earnings releases to assess demand recovery and margin stabilization in the manufacturing chemicals portfolio.

Arvee Laboratories: Trading Window Closes from October 1, 2026 for Q2 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 15 Sep 2026, 08:00 PM

Arvee Laboratories (India) Limited has announced the closure of its trading window starting from October 1, 2026. This restriction is pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, for the declaration of financial results for the period ended September 30, 2026. The window will remain shut until two working days after the financial results are published. Promoters, directors, and designated persons are prohibited from trading the company's securities during this timeframe.

Trading window closes on 1st October, 2026
Pertains to financial results for the period ended 30th September, 2026
Reopens after the next 2 working days following the declaration of results
Applies to Promoters, Directors, Key Managerial Personnel, and Designated Persons

💡 Track the upcoming board meeting announcement date where the company will consider and approve the financial results for the period ended September 30, 2026.

Arvee Laboratories CS & Compliance Officer Raina Singh Resigns Effective September 9, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 09 Sep 2026, 05:29 PM

Arvee Laboratories (India) Limited has announced the resignation of Mrs. Raina Singh from the role of Company Secretary and Compliance Officer (Key Managerial Personnel), effective September 9, 2026. The resignation is attributed to pursuing an alternate career opportunity outside the organization. The company confirmed there are no other material reasons behind her departure. This is a routine secretarial-level transition and does not impact commercial or manufacturing operations.

Resignation effective from the closing of business hours on September 9, 2026
Mrs. Raina Singh served as Company Secretary and Compliance Officer (KMP)
Reason stated is to pursue an alternate career opportunity outside the company
Confirmation provided that no other material reasons exist for the resignation

💡 Track subsequent exchange filings for the appointment of a new Company Secretary and Compliance Officer within the statutory timeframe mandated by SEBI.

Rs 17.23 Cr Revenue: Arvee Labs Reports 130% YoY Growth in Q1 FY27

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 07 Aug 2026, 05:59 PM

Arvee Laboratories reported a strong start to FY27 with Q1 revenue from operations jumping 130% YoY to Rs 17.23 Cr. Net profit surged to Rs 1.69 Cr, a significant recovery from Rs 0.17 Cr in the year-ago period. The performance was heavily driven by the Non-textile segment, which contributed Rs 15.10 Cr (87%) to total revenue. Notably, the Board has postponed the previously proposed Scheme of Arrangement for further review.

Revenue from operations grew 130% YoY to Rs 17.23 Cr from Rs 7.48 Cr.
Net profit increased nearly 10-fold to Rs 1.69 Cr compared to Rs 0.17 Cr in Q1 FY26.
Non-textile segment revenue stood at Rs 15.10 Cr, dwarfing the Textile segment's Rs 2.31 Cr.
Quarterly EPS rose to Rs 1.54 from Rs 0.15 in the corresponding previous quarter.
Board postponed the Scheme of Arrangement to gain a 'better understanding of the matter'.

💡 Investors should monitor the sustainability of this higher revenue run-rate in upcoming quarters and seek clarity on the reasons for postponing the Scheme of Arrangement.

Arvee Laboratories Corrects Trading Window Closure Date to July 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Aug 2026, 02:12 PM

Arvee Laboratories (India) Limited has issued a corrigendum to its previous filing dated July 31, 2026. The company clarified that a typographical error led to the trading window closure being reported as April 1, 2026, whereas the correct date is July 1, 2026. This is a standard administrative correction related to insider trading compliance. There is no impact on the company's financial operations or business fundamentals.

Corrected the trading window closure date to July 1, 2026 (01/07/2026)
Rectified a typographical error from the previous letter dated July 31, 2026
Original incorrect date mentioned was April 1, 2026 (01/04/2026)
Company maintains a small-cap profile with a market capitalization of ₹250 Cr

💡 No action is required as this is a routine administrative correction. Investors should focus on the upcoming quarterly financial results to assess the company's recovery from its recent revenue volatility.

Arvee Laboratories Announces Trading Window Closure from July 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Jun 2026, 07:42 PM

Arvee Laboratories (India) Limited has informed the exchange that its trading window for dealing in company securities will be closed starting July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the quarter ending June 30, 2026. The window will remain closed for all designated persons, including promoters and directors, until 48 hours after the results are made public. This is a standard administrative procedure for listed companies in India.

Trading window closure effective from July 1, 2026
Closure relates to the financial results for the quarter ending June 30, 2026
Restriction applies to Promoters, Directors, and Key Managerial Personnel
Window to reopen 48 hours after the official results declaration

💡 Investors should wait for the announcement of the board meeting date, which will determine when the Q1 FY27 financial results will be released.

Arvee Laboratories FY26 Net Profit Rises 17.6% to ₹2.53 Cr Despite Annual Revenue Dip

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 19 May 2026, 02:46 PM

Arvee Laboratories reported a mixed performance for the financial year ended March 31, 2026, with annual net profit growing to ₹252.63 lakhs from ₹214.74 lakhs in the previous year. While total annual revenue from operations saw an 18% decline to ₹3,151.41 lakhs, the fourth quarter showed a strong recovery with revenue jumping 67% year-on-year to ₹1,080.41 lakhs. The company's non-textile segment remains the primary revenue driver, contributing approximately 86% of the total turnover for the year. Earnings per share (EPS) improved to ₹2.29 from ₹1.95 in the prior fiscal year.

Full-year net profit increased 17.6% to ₹252.63 lakhs compared to ₹214.74 lakhs in FY25.
Q4 FY26 revenue surged to ₹1,080.41 lakhs, a significant jump from ₹645.00 lakhs in Q4 FY25.
Annual EPS rose to ₹2.29 from ₹1.95, reflecting improved bottom-line efficiency.
Non-textile segment contributed ₹2,757.99 lakhs to annual revenue, significantly outperforming the textile segment.
Total assets grew to ₹4,325.71 lakhs as of March 31, 2026, up from ₹3,915.93 lakhs the previous year.

💡 Investors should focus on the strong Q4 recovery and improved profitability margins despite the annual revenue contraction. The growth in the non-textile segment is a key metric to watch for sustained long-term performance.

Arvee Laboratories Clarifies No Material Undisclosed Information Amid Price Movement

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 15 Apr 2026, 05:30 PM

Arvee Laboratories (India) Limited has responded to a clarification request from the National Stock Exchange regarding recent significant fluctuations in its share price. The company officially stated that it is in full compliance with all SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management confirmed that there are no undisclosed material events or information that could be influencing the stock's performance. The company maintains that the price movement is purely market-driven and determined by the actions of shareholders.

NSE issued a surveillance clarification request (Ref: NSE/CM/Surveillance/16816) on April 13, 2026.
Company submitted its formal response on April 15, 2026, denying any undisclosed material developments.
Management confirmed adherence to SEBI Listing Obligations and Disclosure Requirements (LODR).
The company attributed all recent price volatility to external market forces rather than internal corporate actions.

💡 As the company has denied any new material developments, investors should treat the recent price volatility as speculative or market-driven. Monitor the stock for fundamental changes or future earnings reports before making significant position adjustments.

Arvee Laboratories Announces Trading Window Closure Starting April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 12:27 PM

Arvee Laboratories (India) Limited has officially notified the exchange regarding the closure of its trading window for all designated persons starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the period ending March 31, 2026. The window will remain closed until 48 hours after the financial results are made public. This is a standard regulatory procedure for listed companies to prevent insider trading during the sensitive period of financial reporting.

Trading window closure commences on April 1, 2026
Closure pertains to the financial results for the quarter and year ending March 31, 2026
Window will reopen 2 working days after the official declaration of results
Restriction applies to Promoters, Directors, KMPs, and Designated Persons

💡 This is a routine regulatory announcement and requires no immediate action from retail investors. Monitor the company's upcoming earnings release for actual performance data.

Arvee Laboratories Clarifies Recent Stock Price Movement to NSE

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 02:33 PM

Arvee Laboratories has responded to a surveillance query from the National Stock Exchange regarding recent significant fluctuations in its share price. The company officially stated that it is in full compliance with all SEBI Listing Obligations and Disclosure Requirements. Management clarified that there are no undisclosed material events or information that would necessitate a public announcement. Consequently, the company attributed the price movement solely to market-driven factors and shareholder transactions.

NSE issued a clarification request on December 19, 2025, regarding unusual price movement
Company confirmed adherence to SEBI (LODR) Regulations, 2015, in its response dated December 24, 2025
Management explicitly stated there are no material events requiring new disclosures to the exchange
The price movement was categorized as being driven entirely by market participants and shareholders

💡 As the company has denied any undisclosed material developments, investors should avoid speculative trading based on recent price volatility. Focus on fundamental performance and upcoming financial results instead.

Arvee Laboratories Q3 FY26 Net Profit Surges to ₹1.83 Cr, Revenue Up 10% YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Feb 2026, 07:16 PM

Arvee Laboratories reported a strong sequential and year-on-year recovery in Q3 FY26, with revenue reaching ₹977.95 Lakhs compared to ₹345.05 Lakhs in the previous quarter. Net profit for the quarter stood at ₹182.69 Lakhs, a significant jump from ₹15.48 Lakhs in Q3 FY25, though this was aided by a deferred tax credit of ₹66.09 Lakhs. Despite the strong quarter, the nine-month revenue of ₹2,071 Lakhs still lags significantly behind the ₹3,203.72 Lakhs recorded in the same period last year. The non-textile segment continues to be the primary revenue driver, contributing approximately 89% of the total quarterly income.

Revenue from operations grew 9.8% YoY to ₹977.95 Lakhs in Q3 FY26.
Net Profit for the quarter increased to ₹182.69 Lakhs from ₹15.48 Lakhs in the previous year's corresponding quarter.
Quarterly Earnings Per Share (EPS) rose to ₹1.66 from ₹0.14 YoY.
Non-textile segment revenue dominated at ₹881.88 Lakhs, while the textile segment contributed ₹109.71 Lakhs.
Total expenses for the nine-month period decreased to ₹1,966.80 Lakhs from ₹2,970.93 Lakhs YoY.

💡 Investors should view the sharp sequential recovery in revenue and margins as a positive sign, but remain mindful of the overall decline in nine-month performance. Monitor the sustainability of the non-textile segment's growth as it is the critical driver for the company's profitability.

Arvee Laboratories Q3 PAT Surges to ₹1.83 Cr; Revenue Up 10% YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Feb 2026, 07:14 PM

Arvee Laboratories reported a strong recovery in Q3 FY26, with revenue from operations reaching ₹9.78 crore, a 10% increase compared to the same quarter last year and a massive 183% jump sequentially. Net profit saw a significant boost to ₹1.83 crore, aided by improved margins and a deferred tax credit of ₹66.09 lakhs. While the quarterly performance is robust, the nine-month revenue of ₹20.71 crore still trails the previous year's ₹32.04 crore, indicating a slow start to the fiscal year. The non-textile chemical segment continues to be the primary revenue driver, contributing approximately 90% of the total turnover.

Revenue from operations grew 10% YoY to ₹977.95 lakhs and 183% QoQ from ₹345.05 lakhs.
Net Profit (PAT) rose sharply to ₹182.69 lakhs from ₹15.48 lakhs in the year-ago period.
Earnings Per Share (EPS) increased to ₹1.66 for the quarter compared to ₹0.14 YoY.
Non-textile segment contributed ₹881.88 lakhs to revenue with a segment profit of ₹126.94 lakhs.
Nine-month PAT stands at ₹200.61 lakhs, nearly matching the previous year's 9M figure of ₹207.82 lakhs despite lower revenue.

💡 Investors should note the strong sequential turnaround and margin improvement in the non-textile segment. While the quarterly growth is impressive, long-term positions should be weighed against the overall decline in 9-month revenue compared to the previous year.

Arvee Laboratories Issues Corrigendum on Trading Window Closure for Q3 FY26 Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 09 Feb 2026, 02:58 PM

Arvee Laboratories (India) Limited has issued a corrigendum to its previous notice regarding the Board Meeting scheduled for February 13, 2026. The update clarifies a typographical error concerning the trading window closure for insiders. The trading window has been officially closed since January 1, 2026, and will remain so until 48 hours after the declaration of financial results for the quarter ended December 31, 2025. This is a routine regulatory filing to ensure compliance with insider trading norms.

Board Meeting scheduled for February 13, 2026, to approve Q3 FY26 financial results
Trading window for insiders closed effective from January 1, 2026
Trading window to remain closed until 2 working days after the financial result declaration
Corrigendum corrects typographical errors in the previous communication dated February 5, 2026

💡 No action is required as this is a minor administrative correction. Investors should focus on the upcoming financial results scheduled for release on February 13, 2026.

Arvee Laboratories Announces Trading Window Closure Starting January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Dec 2025, 01:33 PM

Arvee Laboratories (India) Limited has officially notified the exchange regarding the closure of its trading window for all designated persons. This closure is effective from January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the company's financial results for this period are declared. This is a standard regulatory procedure to prevent insider trading ahead of earnings announcements.

Trading window closure commences on January 1, 2026
Closure pertains to the financial period ending December 31, 2025
Restriction applies to Promoters, Directors, KMPs, and Designated Persons
Window will reopen 48 hours after the declaration of quarterly financial results

💡 This is a routine regulatory filing with no direct impact on stock fundamentals. Investors should monitor the company's upcoming earnings release for actual performance data.

Arvee Laboratories Clarifies No Undisclosed Material Events Following NSE Price Query

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Dec 2025, 11:48 AM

Arvee Laboratories (India) Limited has responded to a surveillance query from the National Stock Exchange regarding recent significant movements in its share price. In its clarification dated December 24, 2025, the company stated that it is in full compliance with all SEBI disclosure regulations. The company confirmed that there are no undisclosed material events or information that would explain the price volatility. Management noted that the price movement is determined by market participants and shareholders rather than internal corporate actions.

Response to NSE surveillance letter Ref. No. NSE/CM/Surveillance/16199 dated December 19, 2025
Company confirms full compliance with SEBI (LODR) Regulations, 2015
No material information or events remain undisclosed to the exchanges
Stock price movement attributed solely to market forces and shareholder transactions

💡 As the company has denied any undisclosed material developments, investors should focus on fundamentals and avoid speculative trading based on price volatility alone.

View All ARVEE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total Revenue from Operations grew 26.83% YoY to INR 38.49 Cr in FY25. Domestic manufacturing sales grew 34.1% to INR 31.45 Cr, while export manufacturing sales declined 20.9% to INR 5.30 Cr. Domestic trading contributed INR 0.35 Cr and export trading INR 0.34 Cr.

Geographic Revenue Split

Domestic sales (India) account for 81.7% of revenue (INR 31.45 Cr), while Export sales account for 13.8% (INR 5.30 Cr). Other operating income contributes the remaining 4.5%.

Profitability Margins

Net Profit Margin improved from 3.46% in FY24 to 5.58% in FY25. Net Profit grew 104.15% YoY to INR 2.15 Cr, driven by higher revenue and a 23.3% reduction in depreciation expenses (from INR 1.50 Cr to INR 1.15 Cr).

EBITDA Margin

EBITDA Margin was 11.1% in FY25 (INR 4.27 Cr) compared to 11.8% in FY24 (INR 3.58 Cr). Core profitability slightly contracted despite the net profit surge due to higher raw material consumption costs.

Credit Rating & Borrowing

Non-current borrowings stood at INR 1.03 Cr as of March 31, 2025. Finance costs for FY25 were INR 0.25 Cr, representing a marginal 0.5% decrease YoY. Specific credit ratings and interest rate percentages were not disclosed.

⚙️ Operational Drivers

Raw Materials

Chemical raw materials (Specific names like benzene or specialty feedstocks not disclosed) represent 49% of total revenue, totaling INR 18.87 Cr in FY25.

Raw Material Costs

Raw material costs were INR 18.87 Cr in FY25, up from INR 15.12 Cr in FY24 (a 24.8% increase), tracking closely with revenue growth. Procurement is managed to mitigate price volatility in the chemical market.

📈 Strategic Growth

Growth Strategy

The company aims to achieve growth by increasing profitability through operational efficiencies and focusing on its manufacturing segment, which saw 34.1% domestic growth. Management is taking steps to mitigate risks from currency fluctuations and market price volatility to stabilize margins.

Products & Services

Chemical products manufactured and traded for industrial use (Specific product names not disclosed).

Brand Portfolio

Arvee Laboratories.

🌍 External Factors

Industry Trends

The chemical industry is characterized by intense competition and regulatory changes. Arvee is positioning itself by maintaining cost records and following relevant accounting standards, though it faces pressure from market-linked pricing.

Competitive Landscape

Faces 'intense competition' which management notes may limit growth prospects and pricing ability.

Competitive Moat

The company lacks a durable moat; it operates in a highly competitive market where products are subject to prevailing market prices, and it faces significant promoter dependency.

Macro Economic Sensitivity

The business is sensitive to global economic and social conditions which can increase costs and negatively affect stock prices. H1 FY26 results show a 92.82% collapse in PBT, indicating high sensitivity to macro-driven revenue drops.

Geopolitical Risks

Global political conditions are cited as risks that could harm the ability to do business and increase operational costs.

⚖️ Regulatory & Governance

Industry Regulations

Subject to the Companies Act 2013 for cost record maintenance. The company received a secretarial qualification for failing to file the Cost Report on time for FY25.

Taxation Policy Impact

Effective tax rate for FY25 was approximately 25.2% (INR 0.72 Cr tax on INR 2.87 Cr PBT).

Legal Contingencies

The company reports nil pending litigations that would impact its financial position as of March 31, 2025. No material foreseeable losses on long-term contracts were reported.

⚠️ Risk Analysis

Key Uncertainties

Key risks include currency fluctuation, regulatory changes, and manufacturing supply disruptions. The 52.7% YoY revenue drop in H1 FY26 represents a critical uncertainty regarding demand stability.